Standard BioTools Affirms FY2026 Sales Guidance of $80.000M-$85.000M vs $81.504M Est

Benzinga Newsdesk www.benzinga.com Negative 70.3%

Neg 70.3% Neu 0% Pos 0%

Standard BioTools (NASDAQ:LAB) affirms FY2026 sales outlook from $80.000 million-$85.000 million to $80.000 million-$85.000 million vs $81.504 million estimate.